$4.40
4.02% today
Nasdaq, Apr 01, 07:17 pm CET
ISIN
US2307701092
Symbol
CPIX
Sector
Industry

Cumberland Pharmaceuticals Inc. Stock price

$4.23
-0.63 12.96% 1M
+2.95 230.47% 6M
+1.86 78.48% YTD
+2.55 151.79% 1Y
+1.41 50.00% 3Y
+0.60 16.53% 5Y
-2.43 36.49% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-0.18 4.08%
ISIN
US2307701092
Symbol
CPIX
Sector
Industry

Key metrics

Market capitalization $59.09m
Enterprise Value $61.39m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.62
P/S ratio (TTM) P/S ratio 1.56
P/B ratio (TTM) P/B ratio 2.58
Revenue growth (TTM) Revenue growth -4.26%
Revenue (TTM) Revenue $37.87m
EBIT (operating result TTM) EBIT $-7.10m
Free Cash Flow (TTM) Free Cash Flow $-680.00k
Cash position $17.96m
EPS (TTM) EPS $-0.46
Short interest 3.78%
Show more

Is Cumberland Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Cumberland Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Cumberland Pharmaceuticals Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Cumberland Pharmaceuticals Inc.:

Buy
100%

Financial data from Cumberland Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
38 38
4% 4%
100%
- Direct Costs 11 11
4% 4%
30%
26 26
8% 8%
70%
- Selling and Administrative Expenses 23 23
3% 3%
60%
- Research and Development Expense 4.82 4.82
17% 17%
13%
-1.06 -1.06
49% 49%
-3%
- Depreciation and Amortization 6.04 6.04
5% 5%
16%
EBIT (Operating Income) EBIT -7.10 -7.10
10% 10%
-19%
Net Profit -6.48 -6.48
3% 3%
-17%

In millions USD.

Don't miss a Thing! We will send you all news about Cumberland Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cumberland Pharmaceuticals Inc. Stock News

Neutral
PRNewsWire
13 days ago
Ifetroban demonstrated significant 5.4% improvement in cardiac function NASHVILLE, Tenn. , March 19, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on rare diseases, today announced that results from its Phase 2 FIGHT DMD clinical trial were selected for a late-breaking presentation at the Muscular Dystrop...
Neutral
Seeking Alpha
28 days ago
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Molly Aggas – Account Supervisor-Dalton Agency A.J. Kazimi – Chief Executive Officer Todd Anthony – Vice President-Organizational Development John Hamm – Chief Financial Officer Conference Call Participants Operator Good afternoon, and welcome to Cumberland Pharmaceutica...
Neutral
PRNewsWire
28 days ago
2024 highlights include expanded product labeling, key FDA designations and new study publications Recent developments include Phase 2 DMD Study Breakthrough Results and Vibativ China approval  NASHVILLE, Tenn. , March 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands deli...
More Cumberland Pharmaceuticals Inc. News

Company Profile

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Its product include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, and RediTrex. The company was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN.

Head office United States
CEO A. Kazimi
Employees 91
Founded 1999
Website www.cumberlandpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today